HIF-2 α regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth

Kelly L. Covello,¹ James Kehler,⁴ Hongwei Yu,² John D. Gordan,² Andrew M. Arsham,^{2,5} Cheng-Jun Hu,² Patricia A. Labosky,¹ M. Celeste Simon,^{1,2,3,6} and Brian Keith²

¹Department of Cell and Developmental Biology, ²Abramson Family Cancer Research Institute, ³Howard Hughes Medical Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA; ⁴Center for Animal Transgenesis and Germ Cell Research, New Bolton Center, University of Pennsylvania, Philadelphia, Pennsylvania 19348, USA

The division, differentiation, and function of stem cells and multipotent progenitors are influenced by complex signals in the microenvironment, including oxygen availability. Using a genetic “knock-in” strategy, we demonstrate that targeted replacement of the oxygen-regulated transcription factor HIF-1 α with HIF-2 α results in expanded expression of HIF-2 α -specific target genes including Oct-4, a transcription factor essential for maintaining stem cell pluripotency. We show that HIF-2 α , but not HIF-1 α , binds to the *Oct-4* promoter and induces *Oct-4* expression and transcriptional activity, thereby contributing to impaired development in homozygous *Hif-2 α KI/KI* embryos, defective hematopoietic stem cell differentiation in embryoid bodies, and large embryonic stem cell (ES)-derived tumors characterized by altered cellular differentiation. Furthermore, loss of HIF-2 α severely reduces the number of embryonic primordial germ cells, which require *Oct-4* expression for survival and/or maintenance. These results identify *Oct-4* as a HIF-2 α -specific target gene and indicate that HIF-2 α can regulate stem cell function and/or differentiation through activation of *Oct-4*, which in turn contributes to HIF-2 α 's tumor promoting activity.

[Keywords: HIF; hypoxia; HIF-2 α ; Oct-4; VEGF; TGF- α ; stem cells; cancer]

Supplemental material is available at <http://www.genesdev.org>.

Received December 8, 2005; revised version accepted January 11, 2006.

Stem cells are characterized by the ability to self-renew and maintain pluripotency. The POU transcription factor Oct-4 (also known as Oct-3/4 and Pou5F1) is essential for maintaining an undifferentiated cell fate in embryonic stem (ES) cells, the embryonic epiblast, and primordial germ cells (PGCs) (Scholer et al. 1990b; Nichols et al. 1998). Oct-4 also plays a critical role in regulating the differentiation of ES cells and maintaining the pluripotent nature of the blastocyst inner cell mass (ICM). In vitro experiments have demonstrated the importance of maintaining strict Oct-4 expression levels. For example, twofold changes in Oct-4 expression cause ES cells to lose pluripotency and differentiate into trophoderm, mesoderm, neuroectoderm, or endoderm lineages (Niwa et al. 2000; Shimozaaki et al. 2003). Recently, Oct-4 has been shown to function in a complex with Nanog and

Sox2 to activate and repress genes controlling stem cell identity and differentiation (Boyer et al. 2005).

Oct-4 expression is tightly controlled throughout embryogenesis and postnatal life. For example, down-regulation of Oct-4 is required for differentiation of trophoderm and primitive endoderm lineages. At the egg cylinder stage, Oct-4 is expressed in the epiblast and subsequently down-regulated during gastrulation, although expression is maintained in PGCs. Furthermore, correlative evidence suggests that when Oct-4 expression is dysregulated, cloned embryos do not develop normally beyond post-implantation stages (Boiani et al. 2002). In the adult, Oct-4 is generally believed to be expressed exclusively in germ cells; however, recent evidence suggests Oct-4 is also present in adult stem cell populations, such as multipotent adult progenitor cells (MAPCs) and hematopoietic stem cells (Jiang et al. 2002; Tai et al. 2005). Finally, ectopic Oct-4 expression contributes to tumor growth and also drives reversible epithelial dysplasia in transgenic mice (Gidekel et al. 2003; Cheng et al. 2004; Hochedlinger et al. 2005). Currently, the mechanisms and factors regulating *Oct-4* expression have not been fully elucidated.

⁵Present address: Department of Genetics, Cell Biology, and Development, University of Minnesota, Minneapolis, MN 55455, USA.

⁶Corresponding author.

E-MAIL celeste2@mail.med.upenn.edu; FAX (215) 746-5511.

Article and publication are at <http://www.genesdev.org/cgi/doi/10.1101/gad.1399906>.

Stem cells, as well as germ cells and other multipotent progenitors, reside in complex microenvironments, termed niches (Spradling et al. 2001). Stromal cell contacts, extracellular matrix proteins, temperature, and oxygen (O_2) levels in the immediate microenvironment can influence stem cell function and differentiation. In particular, low O_2 levels (hypoxia) promote the survival of neural crest stem cells, hematopoietic stem cells, and human ES cells (Morrison et al. 2000; Studer et al. 2000; Danet et al. 2003; Ezashi et al. 2005). Hypoxia also regulates the number of ICM cells in bovine blastocysts and enhances hemangioblast and hematopoietic progenitor development. (Adelman et al. 1999; Harvey et al. 2004; Ramirez-Bergeron et al. 2004). It is therefore possible that hypoxia mediates its effects on stem cell function by altering Oct-4 expression.

Hypoxia occurs in a number of physiological and pathophysiological settings, particularly when rapid tissue growth exceeds blood supply. For example, embryogenesis occurs in a physiologic “hypoxic” environment (3%–5% O_2). The primary transcriptional regulators of both cellular and systemic hypoxic adaptation in mammals are hypoxia-inducible factors (HIFs). HIFs are heterodimers consisting of a regulated subunit (HIF α) and a constitutive subunit (HIF β , also known as ARNT [aryl hydrocarbon nuclear translocator]) (Wenger and Gassmann 1997). HIFs regulate the expression of at least 180 genes involved in metabolism, cell survival, erythropoiesis, and vascular remodeling (Semenza 2000) by binding to *cis*-acting hypoxia response elements (HREs) located in the enhancers and/or promoters of these genes (Pugh et al. 1991).

The first HIF α subunit identified was HIF-1 α , which is expressed ubiquitously in human and mouse tissues and considered to be the primary regulator of hypoxic responses. The more recent identification of HIF-2 α (also known as endothelial PAS domain protein 1 [EPAS 1], HIF-1-like factor [HLF], and HIF-1-related factor [HRF]) has raised important questions about the relative activity of these factors in mediating hypoxic adaptation. HIF-1 α and HIF-2 α share a high degree of sequence identity, underscored by their shared ability to heterodimerize with ARNT and bind HREs to activate transcription in various *in vitro* reporter assays (Wiesener et al. 1998). Whereas HIF-1 α is broadly expressed, HIF-2 α transcripts are restricted to particular cell types, including vascular endothelial cells, neural crest cell derivatives, lung type II pneumocytes, liver parenchyma, and interstitial cells in the kidney (Ema et al. 1997; Flamme et al. 1997; Tian et al. 1997; Compennolle et al. 2002; Wiesener et al. 2003). Gene targeting experiments in mice have shown that loss of HIF-1 α or HIF-2 α results in strikingly different phenotypes, suggesting that each protein performs unique physiological functions. It is possible that HIF-1 α and HIF-2 α proteins are functionally equivalent but perform different physiological roles due to their distinct expression patterns; alternatively, HIF-1 α and HIF-2 α may regulate overlapping but nonidentical target genes. In studies designed to identify unique HIF-1 α and HIF-2 α target genes, we and others showed that HIF-1 α and HIF-

2 α activate a number of common genes; however, HIF-1 α exclusively induces the hypoxic transcription of glycolytic genes such as phosphoglycerate kinase 1 (*Pgk1*) and aldolase A (*Alda*) (Hu et al. 2003; Wang et al. 2005). Expression profiling of a renal clear cell (RCC) carcinoma line expressing HIF-2 α , but not HIF-1 α , identified a number of putative HIF-2 α target genes, including *Vascular endothelial growth factor* (*Vegf*) and *Transforming growth factor α* (*Tgf- α*) (Gunaratnam et al. 2003; Hu et al. 2003; Wykoff et al. 2004).

To dissect the unique and overlapping roles of HIF-1 α and HIF-2 α more rigorously, we generated “knock-in” ES cells in which a cDNA encoding HIF-2 α was targeted to the *Hif-1 α* locus, generating a *Hif-1 α ^{Hif-2 α KI}* allele, hereafter referred to as *Hif-2 α KI* (Covello et al. 2005). This allele results in expanded HIF-2 α expression under the regulatory control of the *Hif-1 α* locus and replaces HIF-1 α with HIF-2 α , thereby allowing a direct comparison of HIF-1 α and HIF-2 α function. Previous experiments revealed that teratomas derived from homozygous *Hif-2 α KI/KI* ES cells were significantly larger and more vascularized than wild-type tumors, and exhibited increased expression of HIF-2 α target genes, including *Tgf- α* and *Vegf* (Covello et al. 2005). Interestingly, *Hif-2 α KI/KI* tumors displayed a large proportion of undifferentiated cells in addition to a distinctive spectrum of differentiated mesodermal and neural cells.

In this report, we investigate the effects of expanded HIF-2 α expression on embryonic development by generating *Hif-2 α KI* mice. Surprisingly, homozygous *Hif-2 α KI/KI* embryos were recovered at markedly reduced numbers at embryonic day 6.5–7.5 (E6.5–E7.5), exhibited developmental patterning defects, and displayed increased expression of *Vegf*, *Tgf- α* , and *Oct-4*. Increased *Oct-4* mRNA levels in *Hif-2 α KI/KI* embryoid bodies (EBs) correlated with enhanced Oct-4 protein levels and transcriptional activity, and was associated with defects in generating hematopoietic progenitors. Down-regulation of Oct-4 activity in *Hif-2 α KI/KI* cells partly rescued the hematopoietic phenotypes; moreover, Oct-4 inhibition altered the cellular differentiation and diminished the growth of *Hif-2 α KI/KI* teratomas. Finally, *Hif-2 α ^{-/-}* embryos displayed strikingly reduced numbers of PGCs, which require *Oct-4* expression for survival and/or maintenance. Together, our data identify HIF-2 α as an upstream regulator of *Oct-4* expression, and suggest a specific mechanism whereby HIF-2 α can affect stem cell function and promote tumor growth.

Results

Expanded HIF-2 α is deleterious to embryonic development

The *Hif-2 α KI* genetic model was designed as a stringent genetic test of the degree to which HIF-2 α could rescue a *Hif-1 α* -null mutation. Briefly, the *Hif-2 α KI* allele was generated by introducing a cDNA encoding a c-Myc epitope-tagged murine HIF-2 α protein into the first coding exon of the murine *Hif-1 α* gene via homologous recom-

ination in ES cells. ES cells homozygous for *Hif-2 α* *KI* express no HIF-1 α protein, but instead express c-Myc-tagged HIF-2 α under the control of the ubiquitously expressed *Hif-1 α* locus (Covello et al. 2005). Chimeric mice were generated by blastocyst injection, and the *Hif-2 α* *KI* allele was transmitted through the germline. Two separate *Hif-2 α* *KI* ES cell lines were used to generate independent *Hif-2 α* *KI* heterozygous mouse lines, and identical results were obtained from each line. When heterozygous *Hif-2 α* *KI*/+ mice were intercrossed, no live-born homozygous *Hif-2 α* *KI*/KI mice were recovered, and heterozygous *Hif-2 α* *KI*/+ mice were recovered in nearly Mendelian ratios (63.1%, cf. 66.7% expected) (Supplementary Table 1). Embryos from timed matings between *Hif-2 α* *KI*/+ mice were dissected beginning at E9.5. We predicted that if the *Hif-2 α* *KI* allele failed to complement the loss of HIF-1 α expression, then homozygous *Hif-2 α* *KI*/KI embryos would die between E9.5 and E11.5, thereby phenocopying *Hif-1 α* -null mutant embryos (Iyer

et al. 1998; Ryan et al. 1998; Compennolle et al. 2003). Surprisingly, we were unable to recover any homozygous *Hif-2 α* *KI*/KI embryos between E8.5 and E9.5 (Supplementary Table 1, *n* = 92). To control for possible effects of genetic background, we backcrossed the *Hif-1 α* ^{-/-} null mutant allele four times to the SvEvTac strain in which the *Hif-2 α* *KI* mice were generated. Mutant *Hif-1 α* ^{-/-} embryos with characteristic phenotypes were recovered in Mendelian ratios between E8.5 and E9.5 in crosses between heterozygous *Hif-1 α* ^{+/-} mice (Supplementary Fig. 1A,B). Furthermore, whereas heterozygous *Hif-1 α* ^{+/-} embryos were phenotypically indistinguishable from wild-type, heterozygous *Hif-2 α* *KI*/+ embryos exhibited a range of phenotypes between E8.5 and E13.5 (Fig. 1A–F; data not shown). Approximately 50% of *Hif-2 α* *KI*/+ embryos were indistinguishable from wild type, whereas the remainder exhibited various defects, including minor hemorrhaging in the embryo and yolk sac as well as more severe phenotypes such as cardiac effusion and

Figure 1. Disrupted development in *Hif-2 α* *KI* embryos. (A–F) Between E10.5 and E13.5, ~50% of *Hif-2 α* *KI*/+ heterozygous embryos demonstrated a range of phenotypes. At E13.5, *Hif-2 α* *KI*/+ heterozygous yolk sacs and embryos display hemorrhaging (B, arrows) and gross abnormalities (C), compared with wild-type (WT) controls (A). (C) Several embryos disintegrated upon dissection, suggesting they were dead or severely abnormal. At E10.5, *Hif-2 α* *KI*/+ heterozygous embryos displayed phenotypes ranging from subtle hemorrhaging (E, arrow) to cardiac effusion (F, asterisk). A wild-type (WT) E10.5 embryo control is shown in D. (G–K) Comparison of wild-type (WT) (G,H) and homozygous *Hif-2 α* *KI*/KI (I) and presumed homozygous *Hif-2 α* *KI*/+ (J,K) E7.5 embryos. Genotypes of embryos in J and K were inferred from morphological similarity to confirmed *Hif-2 α* *KI*/KI embryos (shown in I) and frequency (10% of total embryos). *Hif-2 α* *KI*/KI embryos displayed improper formation of the epiblast (ep, arrows in H,I,J,K), and embryonic (em) and extraembryonic (ex) cavities, compared with wild type (WT). (L–P) Whole-mount RNA in situ hybridization on E7.5 embryos using probes for the mesodermal marker Brachyury (Bry) (L,M) and visceral endodermal marker α -fetoprotein (AFP) (N–P). In contrast to wild-type (WT) littermate controls (L,N), which display normal mesoderm migration through the primitive streak (bracket in L), *Hif-2 α* *KI*/KI embryos exhibit patterning defects (M) consistent with abnormal gastrulation. Similarly, AFP expression is restricted to the extraembryonic visceral endoderm in wild-type embryos (arrow in N), but maintained in embryonic visceral endoderm in *Hif-2 α* *KI*/KI embryos (O,P).

death (Fig. 1C,F). The segregation data in Supplementary Table 1 indicate, however, that the majority of the phenotypes observed in heterozygous *Hif-2α* *KI/+* embryos did not result in lethality.

By extending our analysis to earlier timepoints, we recovered morphologically aberrant homozygous *Hif-2α* *KI/KI* embryos at E6.5–E7.5 (Fig. 1I), although significantly fewer (10%) than the 25% expected based on Mendelian ratios ($n = 120$). In contrast, *Hif-2α* *KI/KI* blastocysts (E3.5) were recovered at the expected ratios (Supplementary Table 1). These data, coupled with the observation that 18% of the total E6.5–E7.5 decidua from *Hif-2α* *KI/+* heterozygous crosses did not contain a detectable egg cylinder, suggested that the missing *Hif-2α* *KI/KI* embryos were resorbed. Histological analysis of intact E6.5–E7.5 decidua also revealed that 10% of the embryos exhibited an expansion of the epiblast and failed to form typical extraembryonic and embryonic cavities (Fig. 1J,K). Aberrant temporal and spatial expression of mesodermal and visceral endoderm markers (*Brachyury* and α -*Fetoprotein*, respectively) was observed in the few *Hif-2α* *KI/KI* embryos we recovered, suggesting that they failed to maintain normal patterning of embryonic and extraembryonic tissues (Fig. 1L–P). Taken together, these data indicate that ~2/3 of homozygous *Hif-2α* *KI/KI* embryos cannot be recovered at E6.5–E7.5, whereas the remainder display defects associated with aberrant embryonic patterning. The abnormalities observed in *Hif-2α* *KI/KI* embryos are distinct from, and occur earlier than, those attributable to loss of HIF-1 α expression (Supplementary Fig. 1A–E), and appear to result from a gain of HIF-2 α function.

Expanded HIF-2 α expression results in up-regulation of *Vegf*, *Tgf- α* , and *Oct-4*

We hypothesized that the developmental defects observed in homozygous *Hif-2α* *KI/KI* embryos were caused by expanded expression of specific HIF-2 α target genes. Published studies performed on RCC carcinoma lines that express HIF-2 α , but not HIF-1 α , provided a list of target genes whose misregulation might contribute to the *Hif-2α* *KI* embryonic phenotype, including *Vegf*, *Tgf- α* , *Adrenomedullin* (*Adm*), and *N-myc downstream-regulated-1* (*NDRG-1*) (Gunaratnam et al. 2003; Hu et al. 2003; Wykoff et al. 2004). Intriguingly, our analysis revealed that these RCC cells also up-regulated *Oct-4* (*Pou5f1*) in response to hypoxia (Hu et al. 2003), raising the possibility that misregulation of *Oct-4* might contribute to the developmental phenotypes observed in the *Hif-2α* *KI/KI* embryos. As dose-dependent functions of *Oct-4* in ES cells have previously been described (Scholer et al. 1990b; Niwa et al. 2000), we hypothesized that aberrant *Oct-4* expression accounted for the low number of post-implantation *Hif-2α* *KI/KI* embryos recovered in our experiments, as well as their morphological defects.

To determine whether *Oct-4* and other HIF-2 α target genes were overexpressed in *Hif-2α* *KI/KI* embryos, mRNAs from individual E6.5–E7.5 embryos were analyzed by quantitative real-time PCR for transcripts encoding

Hif-1 α , *Hif-2 α* , *Pgk1*, *Vegf*, *Tgf- α* , and *Oct-4* (Fig. 2). Genotyping was conducted on embryo DNA and correlated to mRNA transcript levels for *Hif-1 α* , *Hif-2 α* , and *Pgk1*, a HIF-1 α -specific target gene (Fig. 2A; Hu et al. 2003). Homozygous *Hif-2α* *KI/KI* embryos exhibited <0.25-fold wild-type levels of *Hif-1 α* and *Pgk1*, and a greater than twofold increase in the expression of *Hif-2 α* (Fig. 2A,B). Figure 2A shows a single embryo per each genotype, and Figure 2B illustrates the average levels of *Hif-1 α* and *Hif-2 α* transcripts from pooled embryos ($n = 9$) of a given genotype. Compared with wild-type embryos, homozygous *Hif-2α* *KI/KI* embryos exhibited significantly increased *Vegf*, *Tgf- α* , and *Oct-4* expression, which correlated with a 3.5-fold increase in *Hif-2 α* transcripts (Fig. 2C). Transcript levels were normalized to 18S rRNA transcripts in each sample. Heterozygous *Hif-2α* *KI/+* embryos showed intermediate expression levels of *Tgf- α* and *Oct-4*. Together, these data indicate that *Vegf*, *Tgf- α* , and *Oct-4* mRNA are elevated by expanded HIF-2 α expression in *Hif-2α* *KI* embryos.

At least two mechanisms could account for these results. First, the spatial expression pattern of HIF-2 α target genes could be expanded, resulting in ectopic expression in atypical cell types. Alternatively, target gene transcripts could display normal spatial distribution but become more abundant. To explore these possibilities, we performed whole-mount in situ hybridization (WISH)

Figure 2. Increased *Oct-4*, *Vegf*, and *Tgf- α* expression in *Hif-2α* *KI/KI* embryos. (A) Genotypes of individual E7.5 embryos were determined by PCR on genomic DNA and quantitative RT-PCR analysis of *Hif-1 α* , *Hif-2 α* , and *Pgk1* transcripts. Transcript levels were normalized to 18S rRNA transcripts in each sample. Data are expressed as the ratio of target gene expression in each sample relative to a known wild-type (WT) litter ($n = 8$) that was stage matched. (B) Average levels of *Hif-1 α* and *Hif-2 α* mRNA in embryos pooled by genotype. (C) Average levels of *Oct-4*, *Vegf*, and *Tgf- α* mRNA in embryos pooled by genotype. (D–F) Whole-mount RNA in situ hybridization for *Oct-4* mRNA demonstrated that *Oct-4* is expressed in the embryonic epiblast in both wild-type (WT) and homozygous *Hif-2α* *KI/KI* E7.5 embryos.

to detect *Oct-4* RNA in E7.5 embryos. Mutant embryos exhibited an expression pattern similar to wild type (Fig. 2D–F), with *Oct-4* expression restricted to the embryonic epiblast. Therefore, the phenotypes observed in the *Hif-2 α* *KI* embryos do not appear to correlate with dramatically expanded spatial regulation of *Oct-4*.

Induction of *Vegf* and *Tgf- α* by the *Hif-2 α* *KI* allele in EBs

To further characterize the effects of the *Hif-2 α* *KI* allele on cellular differentiation, we employed an in vitro ES cell-derived EB model. In this system, ES cells are cultured in methylcellulose to generate EBs that produce derivatives of all three germ layers (Keller et al. 1993). This system also provides sufficient material for biochemical analysis, in contrast to the limiting number of arrested E6.5–E7.5 embryos obtained from *Hif-2 α* *KI/+* crosses. Moreover, the EB model allowed us to assess the effects of the *Hif-2 α* *KI* allele on hematopoietic stem cell function (see below). As an additional control for these experiments, we generated a corresponding *Hif-1 α* *KI* allele in which a c-Myc-epitope-tagged HIF-1 α cDNA was introduced into the first coding exon of the murine *Hif-1 α* gene, using the same strategy employed to generate the *Hif-2 α* *KI* allele (Fig. 3A; Supplementary Fig. 2). This *Hif-1 α* *KI* allele controls for potential unforeseen effects of expressing a targeted cDNA from the genomic *Hif-1 α* locus. Immunoprecipitation and immunoblot analysis revealed that the *Hif-1 α* *KI* allele resulted in levels of c-Myc-tagged protein similar to the *Hif-2 α* *KI* allele in hypoxic ES cells (Fig. 3B). Importantly, the *Hif-1 α* *KI* allele showed hypoxic induction of the HIF-1 α -specific target gene *Aldolase A* (*Alda*) to levels comparable to 3.5-d wild-type EBs (Fig. 3C). Embryos derived from the *Hif-1 α* *KI* ES cells appeared normal at E9.5, in contrast to the *Hif-2 α* *KI* embryos (Supplementary Fig. 1).

We focused initially on *Vegf* and *Tgf- α* expression in 3.5-d EBs generated from two independent *Hif-2 α* *KI/KI* ES cell clones. In these experiments, EBs were cultured at 21% O₂. However, given their three-dimensional structure in methylcellulose, they contain hypoxic subdomains (Adelman et al. 1999). *Hif-2 α* *KI/KI* EBs displayed increased *Vegf* and *Tgf- α* expression compared with wild-type and *Hif-1 α* *KI/KI* EBs (Fig. 3D), and the degree of target gene induction was proportional to the level of total *Hif-2 α* transcript. Importantly, *Vegf* and *Tgf- α* induction was specific to *Hif-2 α* *KI/KI* EBs, as the *Hif-1 α* *KI/KI* control expressed *Vegf* and *Tgf- α* transcripts at levels similar to wild type. Immunological assays revealed a corresponding increase in TGF- α protein levels in *Hif-2 α* *KI/KI* EBs derived from both ES cell clones: 5 ± 0.41 -fold and 6 ± 0.35 -fold, respectively. Expression of *Tgf- α* and *Vegf* in *Hif-1 α* ^{−/−} EBs was similar to (or less than) that observed in wild type, indicating that elevated expression in *Hif-2 α* *KI/KI* EBs was a consequence of expanded HIF-2 α and not simply the lack of HIF-1 α (Fig. 3D). In contrast to *Vegf* and *Tgf- α* , other HIF target genes including *erythropoietin* (*Epo*), *Adm*, *adipose differentiation related protein* (*ADRP*), and

Figure 3. Increased *Vegf* and *Tgf- α* expression in *Hif-2 α* *KI/KI* 3.5 d EBs. (A) Schematic of HIF-1 α control knock-in allele, in which a c-Myc-tagged *Hif-1 α* cDNA was targeted to the first coding exon of the murine *Hif-1 α* locus in ES cells. A detailed description is presented in Supplementary Figure 2. (B) Extracts from homozygous *Hif-1 α* *KI/KI* and *Hif-2 α* *KI/KI* ES cells were immunoprecipitated with c-Myc epitope antibodies and then analyzed on Western blots using c-Myc antibodies. Western blot analysis using AKT antibodies confirms that each sample in the immunoprecipitation experiment had equal amounts of input protein. (N) Normoxia (21% O₂); (H) hypoxia (4 h at 1.5% O₂). (C) Quantitative RT-PCR analysis in 3.5-d EBs of *Alda A* transcripts in wild-type (WT) and homozygous *Hif-1 α* *KI/KI*, *Hif-2 α* *KI/KI*, and *Hif-1 α* ^{−/−} EBs. Fold change indicates increases in mRNA in EBs grown at 3.0% O₂ relative to EBs grown at 21% O₂. Transcript levels were normalized to 18S rRNA transcripts in each sample. (D) Real-time PCR analysis in 3.5-d EBs cultured at 21% O₂ indicates increased *Tgf- α* , *Vegf*, and *Hif-2 α* mRNA in two independently derived homozygous *Hif-2 α* *KI/KI* clones. Changes in expression are specific to the *Hif-2 α* *KI* allele, as *Hif-1 α* *KI/KI* clones and *Hif-1 α* ^{−/−} EBs behave similarly to wild type. (*) $p < 0.005$.

NDRG-1 were expressed at levels comparable to wild type (data not shown). Interestingly, *Hif-2 α* transcript levels were decreased in *Hif-1 α* ^{−/−} cells, suggesting that HIF- α subunits may regulate each other's transcript levels, either directly or indirectly. These data indicate that the expanded expression of HIF-2 α from the *Hif-2 α* *KI* allele drives increased expression of specific HIF-2 α target genes in EBs.

HIF-2 α activates *Oct-4* directly

Hif-2 α *KI/KI* 3.5 d EBs also displayed a twofold induction of *Oct-4* transcripts compared with wild-type EBs (Fig. 4A), which correlated to enhanced *Oct-4* protein levels (Fig. 4B). Furthermore, increased *Oct-4* expression was not observed in *Hif-1 α* *KI/KI* or *Hif-1 α* ^{−/−} EBs, suggesting that up-regulation of *Oct-4* was a specific consequence of

expanded HIF-2 α expression (Fig. 4A). Although subtle, the modest induction of Oct-4 protein levels is within the twofold range known to affect ES cell pluripotency and differentiation (Niwa et al. 2000). Oct-4 has been previously reported to activate *Fgf-4*, a preimplantation growth factor required for blastocyst viability (Feldman et al. 1995). Consistent with Oct-4 up-regulation, *Hif-2 α KI/KI* EBs exhibited approximately twofold more *Fgf-4* mRNA than wild type (Fig. 4C). It has also been reported that a twofold increase in Oct-4 levels induces ES cells to form mesoderm and endoderm lineages in vitro (Niwa et al. 2000). Indeed, *Hif-2 α KI/KI* EBs demonstrated a twofold induction of the mesodermal marker *Bry* (Fig. 4C), as well as increases in endodermal markers *Gata-binding protein 4* (*Gata-4*) and *Forkhead box A2* (*FoxA2*) (data not shown). The increased expression of mesoderm markers in *Hif-2 α KI/KI* EBs is distinct from the decreased mesoderm marker expression observed in *Hif-2 α KI/KI* embryos. These apparently contradictory results likely reflect the fact that the *Hif-2 α KI/KI* embryos arrest development around the time of mesoderm formation, whereas *Hif-2 α KI/KI* EBs continue to grow in culture.

HIF-2 α activation of *Oct-4* could be direct or indirect. Sequence analysis of the mouse and human *Oct-4* upstream promoter and enhancer region (Nordhoff et al. 2001) revealed several putative HREs, some of which reside in regions previously reported as conserved between mice and humans (CR1–CR4). We identified one puta-

tive HRE each in CR4 and CR3, one HRE between CR4 and CR3, and three HREs between CR2 and CR1 in the human and mouse promoter (Fig. 4D). Chromatin immunoprecipitation (ChIP) experiments revealed that HIF-2 α occupied the HREs in CR4 and CR3, but not the HREs between CR2 and CR1, in hypoxic human RCC cells (786-O WT-8) that express stabilized HIF-2 α , but not HIF-1 α (data not shown; Maxwell et al. 1999). ChIP experiments in 293 cells that express doxycycline-inducible forms of HIF-1 α and HIF-2 α demonstrated that HIF-2 α , but not HIF-1 α , occupies the HREs in the *Oct-4* promoter and enhancer region (Fig. 4E). Importantly, deletion of these HREs abrogates the hypoxic induction of *Oct-4* (Fig. 4F). Taken together, these data indicate that endogenous HIF-2 α binds to HREs in *Oct-4* regulatory regions in cells and is consistent with the hypothesis that HIF-2 α directly activates *Oct-4* expression in our KI model.

TGF- α inhibition and *Oct-4* knock-down rescues Hif-2 α KI hematopoietic defects.

Next, we employed an in vitro system of hematopoietic differentiation to investigate the effects of expanded HIF-2 α target gene expression on stem cell function. As stated above, ES cells form three-dimensional EBs in methylcellulose, which generate hypoxic subdomains even when maintained in normoxic conditions (Adelman et al. 1999). After 9 d, the EBs can be disaggregated

and plated in the presence of specific growth factors that allow the expansion and differentiation of various hematopoietic colony-forming units (CFUs) representing erythroid (CFU-E), macrophage (CFU-M), granulocyte (CFU-G), and mixed lineage (CFU-GM, CFU-GEMM) progenitors (Keller et al. 1993). Compared with wild-type ES cells, independent homozygous *Hif-2 α KI/KI* ES clones formed significantly fewer CFUs of all hematopoietic lineages (Fig. 5A), giving rise to ~30% of the total CFUs generated by wild-type cells (Fig. 5B). Interestingly, the *Hif-2 α KI/KI* ES cells formed 7.8-fold more secondary EBs compared with wild type, consistent with maintenance of an undifferentiated state. The inability to generate proper numbers of CFUs was specific to EBs derived from *Hif-2 α KI/KI* ES cells, as both *Hif-1 α ^{-/-}* and *Hif-1 α KI/KI* EBs formed a similar number of CFUs compared with wild type (Fig. 5B). Furthermore, knock-down of HIF-2 α in the *Hif-2 α KI/KI* clones rescued the ability to form colonies (Fig. 5B). We observed no difference in proliferation or apoptosis in the wild-type and *Hif-2 α KI/KI* EBs as measured by staining for Ki67 and cleaved caspase-3, respectively (data not shown), suggesting that the *Hif-2 α KI* allele was affecting the formation and/or differentiation of hematopoietic progenitors.

To determine the contribution of *Vegf*, *Tgf- α* , and *Oct-4* to this hematopoietic defect, we used multiple approaches to selectively inhibit *Vegf*, *Tgf- α* , or *Oct-4* function in *Hif-2 α KI/KI* EBs. Treatment of *Hif-2 α KI/KI* EBs with a previously characterized neutralizing antibody against VEGF (Gunaratnam et al. 2003) did not rescue the CFU defect of *Hif-2 α KI/KI* EBs (data not shown). Next, the compound PD153035 was used to inhibit TGF- α signaling by reducing phosphorylation of the epidermal growth factor receptor (EGFR) (Gunaratnam et al. 2003) in a dose-dependent manner. Consistent with increased TGF- α secretion, *Hif-2 α KI/KI* EBs exhibit hyperphosphorylation of the EGFR (Fig. 5C). When TGF- α activity was inhibited in *Hif-2 α KI/KI* EBs to levels equivalent to wild-type EBs, there was an increased ability to form CFUs relative to the untreated controls (~60% of wild type, cf. 30%) (Fig. 5C, lanes 6,9). In contrast, treatment of wild-type EBs with PD153035 inhibited their ability to form CFUs. Importantly, TGF- α inhibition did not affect *Oct-4* or *Hif-2 α* levels (data not shown). This partial restoration of CFU-forming ability suggests that up-regulation of TGF- α is partly responsible for the *Hif-2 α KI* hematopoietic phenotype in EBs. An RNA interference (RNAi) approach was used to

Figure 5. Reversal of *Hif-2 α KI* hematopoietic phenotypes by TGF- α and Oct-4 inhibition. (A) Normoxic day 9 *Hif-2 α KI/KI* EBs form fewer hematopoietic CFUs than wild-type (WT) EBs. Numbers of CFU-E, CFU-M, CFU-G, and CFU-GM, CFU-GEMM progenitors are shown. Homozygous *Hif-2 α KI/KI* EBs form more secondary EBs, compared with wild type. (B) Comparison of total CFU formation in EBs derived from ES cells of different genotype, expressed as a percentage of wild type (WT). Note the statistically significant decrease in the ability of homozygous *Hif-2 α KI/KI* ES cells to form CFUs. This phenotype is specific to the two independent homozygous *Hif-2 α KI/KI* clones, as *Hif-1 α KI/KI* clones, *Hif-1 α ^{-/-}* EBs, and *Hif-2 α KI/KI + HIF-2 α shRNA* clones behave similarly to wild type. (*) $p < 0.005$. (C) Western blot analysis for phosphorylated EGFR revealed inhibition of TGF- α activity by PD153035 in wild-type (WT) and in homozygous *Hif-2 α KI* EBs. *Hif-2 α KI/KI* EBs exhibited hyperphosphorylation of EGFR, consistent with increased TGF- α activity. Reduction in EGFR phosphorylation in wild-type EBs correlated to a decrease in total CFU formation. In contrast, reduction of EGFR phosphorylation in *Hif-2 α KI/KI* EBs correlated to increased CFU formation. Restoration of CFU formation in *Hif-2 α KI/KI* EBs was most notable in samples displaying nearly wild-type levels of EGFR phosphorylation. Total CFU formation is expressed as a percentage of that obtained with EBs derived from wild-type ES cells. (*) $p < 0.005$. (D) Western blot analysis indicating variable knock-down of Oct-4 protein

and activity (*Fgf-4* RNA expression) in EBs derived from homozygous *Hif-2 α KI/KI* ES cell clones expressing *Oct-4* shRNAs. EBs derived from *Hif-2 α KI/KI* ES clones with Oct-4 protein levels similar to wild type (WT) displayed reduced expression of *Fgf-4* RNA, and partial restoration of CFU formation compared with *Hif-2 α KI/KI*. (*) $p < 0.005$. (E) EBs derived from *Hif-2 α KI/KI* ES clones doubly inhibited for Oct-4 and TGF- α show even greater restoration of CFU formation and reduced secondary EB formation compared with *Hif-2 α KI/KI*.

reduce *Oct-4* expression in *Hif-2 α KI/KI* EBs. Stable cell lines were generated in *Hif-2 α KI/KI* ES cells and used to form EBs. As expected, the clones exhibited variable levels of *Oct-4* inhibition: Some displayed modest reduction of *Oct-4* levels compared with parental *Hif-2 α KI/KI* EBs (Fig. 5D, clone A), some demonstrated *Oct-4* levels comparable to wild type (Fig. 5D, clone D), and others displayed an intermediate reduction in *Oct-4* expression (Fig. 5D, clones B and C). Interestingly, a few clones displayed *Oct-4* levels significantly lower than wild type, but appeared morphologically similar to trophectoderm cells and expressed the trophectoderm markers *Hand1* and *Cdx2* (Supplementary Fig. 4), consistent with published data (Niwa et al. 2000).

Oct-4 knock-down in *Hif-2 α KI/KI* EBs correlated with a reduction of *Fgf-4* levels (Fig. 5D), as well as reduced *Bry* expression (data not shown). Next, we measured CFUs in EBs derived from *Hif-2 α KI/KI* clones expressing different *Oct-4* levels. As *Oct-4* levels were reduced, *Hif-2 α KI/KI* clones A–D exhibited an increased ability to form CFUs in this assay (~55% of wild type) (Fig. 5D). Of note, inhibition of *Oct-4* did not affect *Tgf- α* or *Hif-2 α* levels (data not shown). Similar to *TGF- α* inhibition, *Oct-4* knock-down only partly rescued the CFU phenotype, suggesting that *TGF- α* and *Oct-4* function independently to alter hematopoietic cell fate in the *Hif-2 α KI* model. Inhibition of both *TGF- α* and *Oct-4* resulted in a greater number of CFUs (70% of wild type) derived from

Hif-2 α KI/KI EBs than inhibition of either *TGF- α* or *Oct-4* alone (60% and 55%, respectively) (Fig. 5E). Furthermore, inhibition of both *TGF- α* and *Oct-4* reduced the ability of *Hif-2 α KI/KI* cells to form secondary EBs (Fig. 5E). Taken together, these data suggest that up-regulation of *TGF- α* and *Oct-4* is primarily responsible for the *Hif-2 α KI* hematopoietic phenotype observed in EBs.

HIF-2 α promotes tumor growth through Oct-4 induction

We reported previously that teratomas derived from homozygous *Hif-2 α KI/KI* ES cells were more proliferative than their wild-type controls, and were characterized by abundant regions of undifferentiated cells as well as regions marked by differentiated mesoderm and neural cell types (Covello et al. 2005). Further analysis revealed that these *Hif-2 α KI/KI* teratomas exhibited a fourfold increase in *Oct-4* expression (data not shown). To investigate whether *Oct-4* up-regulation by *HIF-2 α* contributes to tumorigenesis, we inhibited *Oct-4* in *Hif-2 α KI/KI* teratomas using short hairpin RNAs (shRNA) (Fig. 6A). Wild-type, homozygous *Hif-2 α KI/KI*, and *Hif-2 α KI/KI* ES cells stably expressing *Oct-4* shRNA hairpins ("*Hif-2 α KI/KI-Oct-4 shRNA*") were injected subcutaneously into NIH-III-immunodeficient mice. As expected, teratomas derived from *Hif-2 α KI/KI* ES cells grew more rapidly, exhibited increased mass, and appeared more hem-

Figure 6. HIF-2 α mediates tumor growth through up-regulation of *Oct-4*. (A) Gross appearance of teratomas resected from nude mice 21 d after subcutaneous injection with wild-type (WT), *Hif-2 α KI/KI* ES cells, and *Hif-2 α KI/KI* ES cells with *Oct-4* shRNA knock-down (*Hif-2 α KI/KI-Oct-4 shRNA*). (B) Final teratoma masses of wild-type (WT), *Hif-2 α KI/KI*, and *Hif-2 α KI/KI-Oct-4 shRNA* teratomas formed after 22 d of growth. Error bars measure standard error of the mean. (*) $p = 0.012$. (C) Western blot analysis of *Oct-4* and β -catenin protein in wild-type (WT), *Hif-2 α KI/KI*, and *Hif-2 α KI/KI-Oct-4 shRNA* teratomas. Data are representative of three independent teratomas per genotype. (D) Ki67 staining of wild-type (WT), *Hif-2 α KI/KI*, and *Hif-2 α KI/KI-Oct-4 shRNA* teratoma sections. Final magnifications are 200 $\times$. (E) Nanog staining of wild type (WT), *Hif-2 α KI/KI*, and *Hif-2 α KI/KI* with *Oct-4* shRNA knock-down teratoma sections.

orrhagic than wild-type controls (Fig. 6A,B). In contrast, *Hif-2 α KI/KI-Oct-4 shRNA* teratomas exhibited reduced mass ($p = 0.012$) and growth rates compared with *Hif-2 α KI/KI* teratomas, but still displayed similar hemorrhaging (Fig. 6A,B).

To assess differences in proliferation or apoptosis, teratomas were analyzed by immunostaining for Ki67 and cleaved caspase-3, respectively (Fig. 6D; data not shown). Both *Hif-2 α KI/KI* and *Hif-2 α KI/KI-Oct-4 shRNA* teratomas demonstrated an increase in Ki67 staining compared with wild type (Fig. 6D). However, the percentage of Ki-67-positive cells in *Hif-2 α KI/KI-Oct-4 shRNA* teratomas was only 1.9-fold greater than wild type, whereas *Hif-2 α KI/KI* teratomas contained 2.5-fold more Ki-67-positive cells than wild type. No quantitative differences in cleaved caspase-3 staining were observed between the three genotypes (data not shown).

Teratoma mRNA and protein analysis confirmed that the elevated levels of Oct-4 in *Hif-2 α KI/KI* tumors were reduced by expression of Oct-4 shRNAs (Fig. 6C). Furthermore, introduction of Oct-4 shRNA was specific, as *Hif-2 α KI/KI-Oct-4 shRNA* teratomas exhibited similar levels of *Vegf*, and *Tgf- α* transcripts compared with the *Hif-2 α KI/KI* tumors (data not shown). Interestingly, Oct-4 inhibition also reduced elevated β -catenin levels in the *Hif-2 α KI/KI* tumors, supporting a recent report that places β -catenin downstream of Oct-4 in tumorigenesis (Fig. 6C; Hochedlinger et al. 2005).

We have demonstrated previously that *Hif-2 α KI/KI* tumors contained undifferentiated cell types, as well as an abundance of mesodermal and neural cells, compared with wild type (Covello et al. 2005). To investigate the role of Oct-4 in altering the spectrum of cell types present, *Hif-2 α KI/KI-Oct-4 shRNA* tumor sections were evaluated by standard histological methods. Consistent with the hypothesis that Oct-4 is influencing the *Hif-2 α KI/KI* tumors cell fate, we observed fewer undifferentiated cell populations as revealed by Nanog immunostaining (Fig. 6E; Supplementary Fig. 4), as well as less bone, cartilage, Schwann cells, and ganglia when Oct-4 levels were inhibited by shRNA (Fig. 6D,E; Supplementary Fig. 4).

HIF-2 α activation of Oct-4 is necessary for PGC development

Taken together, our data suggest that expanded HIF-2 α expression is sufficient for up-regulation of Oct-4. To determine whether HIF-2 α maintains Oct-4 expression in normal physiological settings, we examined *Oct-4* expression in cells devoid of HIF-2 α function. *Oct-4* transcripts were hypoxically induced in wild-type and *Hif-1 α ^{-/-}* 3.5-d EBs, but this response was dramatically attenuated in *Hif-2 α ^{-/-}* EBs (Fig. 7A). Next, we asked whether HIF-2 α plays a regulatory role in PGCs, which retain *Oct-4* expression during embryonic development. *Hif-2 α ^{-/-}* embryos display a significant decrease in PGC numbers, as visualized by alkaline phosphatase (AP) staining of E8.5 embryos (Fig. 7B–D). Wild-type and heterozygous E8.5 *Hif-2 α ^{+/-}* embryos (s7–s11) displayed

Figure 7. HIF-2 α is required for *Oct-4* expression and normal PGC numbers. (A) Real-time PCR analysis demonstrates increased hypoxic induction (1.5% O₂ for 16 h) of *Oct-4* mRNA in wild-type (WT) and *Hif-1 α ^{-/-}* 3.5-d EBs, which is diminished in *Hif-2 α ^{-/-}* EBs. (B–D) PGCs in E8.5 embryos revealed by AP staining. Arrows point to representative PGCs in C and D. In contrast to wild-type (WT) and heterozygous *Hif-2 α ^{+/-}* littermate controls (C), somite-matched *Hif-2 α ^{-/-}* embryos exhibit reduced numbers of PGCs (D). (E) Quantification of PGC numbers in somite-matched E8.5 (s7–s11) embryos. (F) PGCs in E12.5 genital ridges dissected from embryos revealed by AP staining. (G) Proposed model for regulation of *Oct-4* by HIF-2 α . In PGCs, the *Oct-4* locus is expressed and regulated by HIF-2 α . The *Oct-4* locus is also expressed in ES cells; however, HIF-2 α activity is normally restricted or repressed in these cells (C.-J. Hu, S. Iyer, A. Sataur, K.L. Covello and M.C. Simon, in prep.). In differentiating somatic cells, the *Oct-4* locus adopts a closed conformation and is not expressed. At this point, HIF-2 α regulates other target genes (e.g., *Vegf*) without modulating *Oct-4* levels. In homozygous *Hif-2 α KI/KI* embryos, EBs, and teratomas, expanded HIF-2 α expression results in up-regulation of *Oct-4* and other targets. HIF-2 α -mediated expression of an inappropriately derepressed *Oct-4* locus in transformed cells could similarly modulate cancer stem cell identity and tumor progression.

49.8 ± 4.4 PGCs per embryo, whereas littermate somite-matched *Hif-2 α ^{-/-}* embryos exhibited only 8.1 ± 2.2 PGCs (Fig. 7B). A dramatic defect was also observed in genital ridges of E12.5 mutant embryos (Fig. 7E,F). This defect may be caused by decreased PGC survival, as previously reported for PGCs in which Oct-4 was deleted

(Kehler et al. 2004). In summary, HIF-2 α is required for normal *Oct-4* expression in EBs, and loss of HIF-2 α negatively affects PGC formation and/or maintenance in embryos.

Discussion

We demonstrate here that HIF-2 α is a direct upstream regulator of Oct-4, a transcription factor essential for maintaining ES and ICM cells in an undifferentiated state. Our data also provide a molecular mechanism to explain how hypoxia can regulate stem cell function in both normal and pathophysiological settings. Normal Oct-4 expression is tightly regulated and generally restricted to cells of the embryonic epiblast, ES cells, PGCs, and possibly adult stem cells. Precise Oct-4 protein levels are critical for peri-implantation development (Nichols et al. 1998), and even subtle changes in Oct-4 expression can profoundly alter cellular differentiation in the early embryo (Boiani et al. 2002; Ramos-Mejia et al. 2005). Embryos homozygous for the *Hif-2 α KI* allele were recovered in strikingly sub-Mendelian ratios, were morphologically aberrant, and exhibited increased expression of HIF-2 α target genes, most notably *Oct-4*. A similar loss of post-implantation embryos was associated with aberrant Oct-4 expression in cloned mouse embryos (Boiani et al. 2002) or transgenic overexpression of HIF-2 α (Supplementary Fig. 5). Increased expression of *Oct-4* and *Tgf- α* also compromised the ability of *Hif-2 α KI/KI* EBs to generate functional progenitors from hematopoietic stem cells. Our data demonstrate that HIF-2 α regulates stem cell function by controlling Oct-4 expression in multiple settings. Interestingly, this effect appears to be specific for HIF-2 α , as HIF-1 α does not regulate *Oct-4* in our experiments.

We also demonstrate that HIF-2 α is required for production, survival, and/or maintenance of PGCs, the principal cell type known to express Oct-4 in post-implantation embryos (Scholer et al. 1990a). In fact, HIF-2 α is expressed in multiple tissues (including blastocyst stage embryos, E7.5 embryos, and PGCs) where Oct-4 is known to play a pivotal role (data not shown). It is not yet clear whether HIF-2 α -mediated Oct-4 expression also plays a role in adult stem cells, as the embryonic or perinatal lethality of most *Hif-2 α ^{-/-}* mice precludes a direct test of this hypothesis. Interestingly, a small number of *Hif-2 α ^{-/-}* mice bearing a specific genetic background survive for several weeks but ultimately succumb to complex pathologies (Scortegagna et al. 2003, 2005). These mice display decreased levels of hematopoietic progenitors, correlated to a decrease in Epo levels (Scortegagna et al. 2003, 2005). As Epo expression was similar in the *Hif-2 α KI/KI*, wild-type, and *Hif-1 α KI/KI* EBs, however, it appears unlikely that Epo plays a major role in the defects we observe.

Our data suggest the model shown in Figure 7G, which proposes that the *Oct-4* promoter is maintained in an open conformation in particular cells of preimplantation embryos and PGCs, and is thereby sensitive to regulation by HIF-2 α . Our model also predicts that the *Oct-4*

locus adopts a closed or “silent” conformation in differentiating embryonic somatic cells, making it refractory to regulation by HIF-2 α , which can nevertheless regulate *Vegf* and *Tgf- α* and other important target genes. We propose that expanded expression of HIF-2 α in homozygous *Hif-2 α KI/KI* embryos results in inappropriate maintenance of *Oct-4* transcription, which underlies the developmental defects we observe. As *Oct-4* is expressed in ES cells, however, our results raise the question of how hypoxic ES cells avoid *Oct-4* induction by stabilized HIF-2 α and the consequent loss of pluripotency. We have recently discovered that although HIF-2 α is clearly stabilized in hypoxic ES cells, it is rendered transcriptionally inactive by one or more specific repressors (C.-J. Hu, S. Iyer, A. Sataur, K.L. Covello, and M.C. Simon, in prep.). Repression of HIF-2 α activity would protect against *Oct-4* induction and consequent differentiation of blastocyst ICM cells in the hypoxic uterine microenvironment.

The relatively subtle phenotypes of heterozygous *Hif-2 α KI/+* embryos, which still express HIF-1 α , suggest that induction of *Oct-4* and *Tgf- α* by a single *Hif-2 α KI* allele is insufficient to overcome a threshold necessary to arrest development. Alternatively, HIF-1 α may directly inhibit the activation of *Oct-4* through competition for cofactors or other mechanisms. However, this appears unlikely as embryos with transgenic HIF-2 α overexpression show phenotypes similar to the *Hif-2 α KI* embryos (Supplementary Fig. 5).

The degree to which increased expression of TGF- α VEGF and other specific HIF-2 α targets also mediate the embryonic phenotypes we observe is currently unknown, although the fact that embryos overexpressing VEGF develop to E13.5 (Miquerol et al. 2000) suggests that it is not the primary factor effecting development in our model. Future experiments combining the *Hif-2 α KI* allele with either *Oct-4* or *Tgf- α* loss-of-function alleles in murine embryos (analogous to those in Fig. 5) will be required to determine the role of each gene in the *Hif-2 α KI* model.

The specific induction of *Oct-4* by HIF-2 α provides a novel mechanism to explain recent observations that HIF-2 α promotes tumor growth more effectively than HIF-1 α . HIF-1 α and HIF-2 α are overexpressed in a large number of human tumor types, including brain, breast, RCC carcinomas, pheochromocytomas, astrocytomas, and non-small-cell lung cancers (Favier et al. 2001; Giatromanolaki et al. 2001; Jaakkola et al. 2001; Khatua et al. 2003). Several experiments have shown that expression of HIF-2 α promotes more rapid growth of RCC xenografts (Kondo et al. 2002, 2003; Maranchie et al. 2002; Raval et al. 2005) and ES cell-derived teratomas (Covello et al. 2005) than does expression of HIF-1 α . The degree to which this generalization extends is not yet clear, but the differential activity of HIF-2 α in these assays has usually been ascribed to expression of target genes, including *Vegf* and *Tgf- α* (Gunaratnam et al. 2003). Whereas expanded expression of HIF-2 α in RCC and *Hif-2 α KI* teratoma models is clearly correlated with more rapid tumor growth, Acker et al. (2005) provide evidence

that HIF-2 α can act instead as a tumor suppressor in rat glioma xenografts. The explanations for the apparent discrepancies with our data are not yet clear, but we suggest that subtle differences in the spectrum of HIF-2 α targets expressed in specific cell types may produce significantly different growth phenotypes; future work will be required to clarify these points. Finally, we observed a subtle decrease in HIF-2 α transcript levels in *Hif-1 α ^{-/-}* ES cells, suggesting that the HIF- α subunits may regulate each other's expression. Interestingly, Raval et al. (2005) report cross-regulation of HIF- α subunits at the protein level in RCC cell lines, although this is not reflected by changes in mRNA expression. Elucidation of the different mechanisms by which HIF- α subunits modulate the function of other family members in specific cell types will be an important question for future studies.

Our data suggest that induction of *Oct-4* by HIF-2 α could maintain hypoxic tumor cells in a more undifferentiated and malignant state. For example, the *Oct-4* locus may regain an open conformation in dedifferentiated transformed cells or cancer stem cells, thereby rendering it susceptible to regulation by HIF-2 α . Hypoxic induction of *Oct-4* may, in turn, promote expansion of an undifferentiated cell population, promote mesodermal identity, and/or stimulate dedifferentiation of terminally differentiated cells (Niwa et al. 2000; Jogi et al. 2002). Data from the *Hif-2 α KI/KI* teratomas support this idea; specifically, *Hif-2 α KI/KI* tumors exhibited increased *Oct-4* and *Nanog* expression and contained undifferentiated cell types, as well as an abundance of mesodermal and neural cells (Covello et al. 2005). The range of cell types we observed in *Hif-2 α KI/KI* teratomas is similar to that described in tumors derived from ES cells that express *Oct-4* in a doxycycline-inducible manner (Gidekel et al. 2003). *Oct-4* protein is also elevated in various types of testicular germ cell tumors, where it regulates growth in a dose-dependent manner (Gidekel et al. 2003). Our results predict that hypoxic *Oct-4* expression may contribute to the progression of multiple tumor types including breast, pancreas, colon, and liver (Monk and Holding 2001; Tai et al. 2005). Notably, a recent report demonstrated that ectopic expression of *Oct-4* in mice was sufficient to cause epithelial dysplasia, which represents an early stage in the development of carcinomas (Hochedlinger et al. 2005). Our findings suggest that hypoxia can regulate the activity and differentiation of cancer stem cells and their progeny through HIF-2 α -mediated control of *Oct-4* expression. If true, then inhibiting HIF-2 α activity might reduce *Oct-4* levels below a threshold required to maintain stem cell identity, thereby promoting cellular differentiation and/or tumor dormancy.

In conclusion, we identify *Oct-4* as a novel HIF-2 α target and demonstrate that expanded expression of HIF-2 α is sufficient for up-regulation of *Oct-4*, *Tgf- α* , and *Vegf* in different biological contexts, including embryonic development and tumor growth (Covello et al. 2005). These data provide the initial connection between hypoxia (HIF-2 α) and a factor critical for stem cell maintenance (*Oct-4*) and novel insight into the regulation of

stem cells in normal development and tumor progression. Finally, these data suggest that targeting HIF-2 α activity may be a useful strategy for modulating stem cell function, and possibly cancer stem cell differentiation, through alteration of *Oct-4* expression.

Materials and methods

Embryo collection and WISH

Timed matings were performed on heterozygous *Hif-2 α KI/+* intercrosses. Embryos were harvested at E6.5–E13.5 and analyzed by gross morphology and H&E or WISH. For WISH, embryos were fixed in 4% PFA and dehydrated through a PBST/methanol series. WISH was performed using Costar 12 well inserts as previously described (Wilkinson 1992). Digoxigenin labeled RNA probes were synthesized using -Digoxigenin RNA kit according to manufacturer's protocol (Roche). Embryos were photographed and then genotyped by PCR using primers specific for the *Hif-2 α KI* allele. Briefly, to purify DNA, embryos were incubated for 6 h at 55°C in 50 mM Tris (pH 8.3), 7.5 mM MgCl₂, 0.5 mg/mL gelatin, and 100 μ g/mL Proteinase K.

Quantitative RT-PCR

Total RNA was purified from wild-type and KI ES cells, EBs, or embryos using Trizol and micro-RNAeasy kit (Qiagen). Mixed Oligo-d(T)₁₅ and ribosomal 18S RNA-specific primers were used to generate single-stranded cDNAs, which were assayed for levels of *Vegf-A*, *Pgk*, *Alda*, *Tgf- α* , *Oct-4*, *Egf-4*, and 18S transcripts as previously described (Covello et al. 2005).

Protein analysis

c-Myc epitope-tagged HIF-1 α and HIF-2 α protein was immunoprecipitated using a c-Myc polyclonal antibody (Cell Signaling, Inc.) according to the manufacturer's protocol. Protein levels for *Oct-4* (Santa Cruz), EGFR (Cell Signaling), phospho-EGFR (Cell Signaling), and β -catenin (Transduction Labs) were determined by Western blot as previously described (Covello et al. 2005).

ChIP and reporter assays

ChIP experiments were performed as previously described (Letting et al. 2003). Briefly, 1×10^7 786-O cells and 293 cells were grown for 16 h in hypoxic conditions. Cells were cross-linked in 0.4% formaldehyde for 10 min at room temperature. Cells were washed five times in PBS, sonicated, precleared, and immunoprecipitated with HIF-2 α or c-myc antibody. Beads were washed and DNA/protein complexes eluted. Cross-links were reversed, and protein was digested with 20 mg/mL proteinase K. DNA was purified by phenol/chloroform extraction and ethanol precipitation. *Oct-4* reporter constructs and assays were performed as previously described (Yeom et al. 1996).

In vitro differentiation and replatings

EB and hematopoietic differentiation assays were performed as originally described (Adelman et al. 1999). Briefly, gelatin-adapted ES cells were plated in base methylcellulose containing 10% serum, 500 U/mL rhIL-1, 5 ng/mL rmIL-3, 10 μ g/mL insulin, 200 μ g/mL transferrin, and 104 M monothioglycerol and allowed to differentiate for 3.5–9 d. The cells were plated on day 0 and allowed to form EBs for 3.5 d (mRNA experiments) or 9 d (for replating experiments, see below). Exogenous TGF- α (1–500

pM) or inhibitors for TGF- α (1–10 μ M) (Calbiochem) and VEGF (0–80 μ M) (Calbiochem) were added as described (Gunaratnam et al. 2003). After 9 d, EBs were washed free of methylcellulose with PBS and disaggregated with trypsin and shearing, using a 21-gauge needle and syringe. Cells were replated into a secondary complete methylcellulose (Stem Cell Technologies, catalog no. 3434). The number of cells plated was equal to the number of cells in 50 EBs derived from wild-type ES cells. Hematopoietic colonies were counted after 6 d.

Oct-4 RNAi

As previously described for expression of shRNAs, annealed DNA oligonucleotides corresponding to nucleotides 670–688 of *Oct-4* were cloned behind the human H1 RNA promoter in the pRetro-H1G vector (Velkey and O'Shea 2003). Upon electroporation of *Hif-2 α KI/KI* ES cells, stable cell lines were selected by treatment at 2 μ g/mL puromycin. GFP-positive *Hif-2 α KI/KI* ES clones were picked under a microscope, expanded, and screened by *Oct-4* RNA and Oct-4 protein.

Teratoma assay and immunohistochemistry

ES cells (5×10^6) in 100 μ L of PBS were injected subcutaneously into the dorsal area of 4- to 6-wk-old NIH-III-immunodeficient mice (Charles River). Tumors were measured every 2–3 d with calipers in the two greatest dimensions to calculate tumor growth over a 21-d period. At 21 d, tumors were harvested, photographed, weighed, fixed in 4% paraformaldehyde, and processed for histological analysis. Tumor samples were sectioned and stained as previously described (Covello et al. 2005). Primary antibodies used were Nanog (Chemicon), cleaved caspase-3 (Cell Signaling, Inc.), Ki-67 (Novocastra), CD34 (Pharmingen), Oct-4 (Santa Cruz), and β -catenin (NeoMarkers).

PGC analysis

Embryos were isolated from litters of *Hif-2 α ^{+/-}* intercrosses at E8.5–E12.5. All embryos used for analysis were somite matched. For AP staining, the posterior portions of E8.5 embryos and E12.5 genital ridges were fixed with 4% PFA, washed three times with PBS, and then stained with AP solution (naphthyl phosphate/fast red TR) at room temperature. They were then rinsed in water, post-fixed in 4% PFA, and photographed. PGC isolation and RT-PCR analysis was performed as previously described (Saitou et al. 2002). Briefly, E12.5 genital ridges were dissected from embryos. Genital ridges were placed in a saline/EDTA plus glucose solution to dissociate germ cells from the stroma.

Statistical analysis

Error bars represent standard error of the mean. Statistical analyses were done by χ^2 analysis and Student's *t*-test. Statistical significance was defined as $P < 0.005$.

Acknowledgments

We thank Anja Runge, Mercy Gohil, and Kim Tremblay for technical assistance. Thanks to Hans Scholer for providing the Oct-4 reporter plasmids. Special thanks to Marisa Bartolomei, Dan Kessler, and members of the Simon laboratory for thoughtful discussions and reading of the manuscript. This research was supported by National Institutes of Health Grant HL66130 (M.C.S. and B.K.), the American Heart Association (K.L.C.) and

the Abramson Family Cancer Research Institute. M.C.S. is an investigator of the Howard Hughes Medical Institute.

References

- Acker, T., Diez-Juan, A., Aragonés, J., Tjwa, M., Brusselmans, K., Moons, L., Fukumura, D., Moreno-Murciano, M.P., Herbert, J.M., Burger, A., et al. 2005. Genetic evidence for a tumor suppressor role of HIF-2 α . *Cancer Cell* **8**: 131–141.
- Adelman, D.M., Maltepe, E., and Simon, M.C. 1999. Multilineage embryonic hematopoiesis requires hypoxic ARNT activity. *Genes & Dev.* **13**: 2478–2483.
- Boiani, M., Eckardt, S., Scholer, H.R., and McLaughlin, K.J. 2002. Oct4 distribution and level in mouse clones: Consequences for pluripotency. *Genes & Dev.* **16**: 1209–1219.
- Boyer, L.A., Lee, T.I., Cole, M.F., Johnstone, S.E., Levine, S.S., Zucker, J.P., Guenther, M.G., Kumar, R.M., Murray, H.L., Jenner, R.G., et al. 2005. Core transcriptional regulatory circuitry in human embryonic stem cells. *Cell* **122**: 947–956.
- Cheng, L., Thomas, A., Roth, L.M., Zheng, W., Michael, H., and Karim, F.W. 2004. OCT4: A novel biomarker for dysgerminoma of the ovary. *Am. J. Surg. Pathol.* **28**: 1341–1346.
- Compernelle, V., Brusselmans, K., Acker, T., Hoet, P., Tjwa, M., Beck, H., Plaisance, S., Dor, Y., Keshet, E., Lupu, F., et al. 2002. Loss of HIF-2 α and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. *Nat. Med.* **8**: 702–710.
- Compernelle, V., Brusselmans, K., Franco, D., Moorman, A., Dewerchin, M., Collen, D., and Carmeliet, P. 2003. Cardia bifida, defective heart development and abnormal neural crest migration in embryos lacking hypoxia-inducible factor-1 α . *Cardiovasc. Res.* **60**: 569–579.
- Covello, K.L., Simon, M.C., and Keith, B. 2005. Targeted replacement of hypoxia-inducible factor-1 α by a hypoxia-inducible factor-2 α knock-in allele promotes tumor growth. *Cancer Res.* **65**: 2277–2286.
- Danet, G.H., Pan, Y., Luongo, J.L., Bonnet, D.A., and Simon, M.C. 2003. Expansion of human SCID-repopulating cells under hypoxic conditions. *J. Clin. Invest.* **112**: 126–135.
- Ema, M., Taya, S., Yokotani, N., Sogawa, K., Matsuda, Y., and Fujii-Kuriyama, Y. 1997. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1 α regulates the VEGF expression and is potentially involved in lung and vascular development. *Proc. Nat. Acad. Sci.* **94**: 4273–4278.
- Ezashi, T., Das, P., and Roberts, R.M. 2005. Low O₂ tensions and the prevention of differentiation of hES cells. *Proc. Nat. Acad. Sci.* **102**: 4783–4788.
- Favier, J., Kempf, H., Corvol, P., and Gasc, J.M. 2001. Coexpression of endothelial PAS protein 1 with essential angiogenic factors suggests its involvement in human vascular development. *Dev. Dyn.* **222**: 377–388.
- Feldman, B., Poueymirou, W., Papaioannou, V.E., DeChiara, T.M., and Goldfarb, M. 1995. Requirement of FGF-4 for postimplantation mouse development. *Science* **267**: 246–249.
- Flamme, I., Frohlich, T., von Reutern, M., Kappel, A., Damert, A., and Risau, W. 1997. HRF, a putative basic helix-loop-helix-PAS-domain transcription factor is closely related to hypoxia-inducible factor-1 α and developmentally expressed in blood vessels. *Mech. Dev.* **63**: 51–60.
- Giatromanolaki, A., Koukourakis, M.I., Sivridis, E., Turley, H., Talks, K., Pezzella, F., Gatter, K.C., and Harris, A.L. 2001. Relation of hypoxia inducible factor 1 α and 2 α in operable

- non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. *Br. J. Cancer* **85**: 881–890.
- Gidekel, S., Pizov, G., Bergman, Y., and Pikarsky, E. 2003. Oct-3/4 is a dose-dependent oncogenic fate determinant. *Cancer Cell* **4**: 361–370.
- Gunaratnam, L., Morley, M., Franovic, A., de Paulsen, N., Mekhail, K., Parolin, D.A., Nakamura, E., Lorimer, I.A., and Lee, S. 2003. Hypoxia inducible factor activates the transforming growth factor- α /epidermal growth factor receptor growth stimulatory pathway in VHL^{-/-} renal cell carcinoma cells. *J. Biol. Chem.* **278**: 44966–44974.
- Harvey, A.J., Kind, K.L., Pantaleon, M., Armstrong, D.T., and Thompson, J.G. 2004. Oxygen-regulated gene expression in bovine blastocysts. *Biol. Reprod.* **71**: 1108–1119.
- Hochedlinger, K., Yamada, Y., Beard, C., and Jaenisch, R. 2005. Ectopic expression of oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. *Cell* **121**: 465–477.
- Hu, C.J., Wang, L.Y., Chodosh, L.A., Keith, B., and Simon, M.C. 2003. Differential roles of hypoxia-inducible factor 1 α (HIF-1 α) and HIF-2 α in hypoxic gene regulation. *Mol. Cell. Biol.* **23**: 9361–9374.
- Iyer, N.V., Kotch, L.E., Agani, F., Leung, S.W., Laughner, E., Wenger, R.H., Gassmann, M., Gearhart, J.D., Lawler, A.M., Yu, A.Y., et al. 1998. Cellular and developmental control of O₂ homeostasis by hypoxia-inducible factor 1 α . *Genes & Dev.* **12**: 149–162.
- Jaakkola, P., Mole, D.R., Tian, Y.M., Wilson, M.I., Gielbert, J., Gaskell, S.J., Kriegsheim, A., Hebestreit, H.F., Mukherji, M., Schofield, C.J., et al. 2001. Targeting of HIF- α to the von Hippel-Lindau ubiquitylation complex by O₂-regulated prolyl hydroxylation. *Science* **292**: 468–472.
- Jiang, Y., Jahagirdar, B.N., Reinhardt, R.L., Schwartz, R.E., Keene, C.D., Ortiz-Gonzalez, X.R., Reyes, M., Lenvik, T., Lund, T., Blackstad, M., et al. 2002. Pluripotency of mesenchymal stem cells derived from adult marrow. *Nature* **418**: 41–49.
- Jogi, A., Ora, I., Nilsson, H., Lindeheim, A., Makino, Y., Poellinger, L., Axelsson, H., and Pahlman, S. 2002. Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype. *Proc. Nat. Acad. Sci.* **99**: 7021–7026.
- Kehler, J., Tolkunova, E., Koschorz, B., Pesce, M., Gentile, L., Boiani, M., Lomeli, H., Nagy, A., McLaughlin, K.J., Scholer, H.R., et al. 2004. Oct4 is required for primordial germ cell survival. *EMBO Rep.* **5**: 1078–1083.
- Keller, G., Kennedy, M., Papayannopoulou, T., and Wiles, M.V. 1993. Hematopoietic commitment during embryonic stem cell differentiation in culture. *Mol. Cell. Biol.* **13**: 473–486.
- Khatua, S., Peterson, K.M., Brown, K.M., Lawlor, C., Santi, M.R., LaFleur, B., Dressman, D., Stephan, D.A., and MacDonald, T.J. 2003. Overexpression of the EGFR/FKBP12/HIF-2 α pathway identified in childhood astrocytomas by angiogenesis gene profiling. *Cancer Res.* **63**: 1865–1870.
- Kondo, K., Klcio, J., Nakamura, E., Lechpammer, M., and Kaelin Jr., W.G. 2002. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. *Cancer Cell* **1**: 237–246.
- Kondo, K., Kim, W.Y., Lechpammer, M., and Kaelin Jr., W.G. 2003. Inhibition of HIF2 α is sufficient to suppress pVHL-defective tumor growth. *PLoS Biol.* **1**: E83.
- Letting, D.L., Rakowski, C., Weiss, M.J., and Blobel, G.A. 2003. Formation of a tissue-specific histone acetylation pattern by the hematopoietic transcription factor GATA-1. *Mol. Cell. Biol.* **23**: 1334–1340.
- Maranchie, J.K., Vasselli, J.R., Riss, J., Bonifacino, J.S., Linehan, W.M., and Klausner, R.D. 2002. The contribution of VHL substrate binding and HIF1- α to the phenotype of VHL loss in renal cell carcinoma. *Cancer Cell* **1**: 247–255.
- Maxwell, P.H., Wiesener, M.S., Chang, G.W., Clifford, S.C., Vaux, E.C., Cockman, M.E., Wykoff, C.C., Pugh, C.W., Maher, E.R., and Ratcliffe, P.J. 1999. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. *Nature* **399**: 271–275.
- Miquerol, L., Langille, B.L., and Nagy, A. 2000. Embryonic development is disrupted by modest increases in vascular endothelial growth factor gene expression. *Development* **18**: 3941–3946.
- Monk, M. and Holding, C. 2001. Human embryonic genes re-expressed in cancer cells. *Oncogene* **20**: 8085–8091.
- Morrison, S.J., Csete, M., Groves, A.K., Melega, W., Wold, B., and Anderson, D.J. 2000. Culture in reduced levels of oxygen promotes clonogenic sympathoadrenal differentiation by isolated neural crest stem cells. *J. Neurosci.* **20**: 7370–7376.
- Nichols, J., Zevnik, B., Anastasiadis, K., Niwa, H., Klewe-Nebenius, D., Chambers, I., Scholer, H., and Smith, A. 1998. Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. *Cell* **95**: 379–391.
- Niwa, H., Miyazaki, J., and Smith, A.G. 2000. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. *Nat. Genet.* **24**: 372–376.
- Nordhoff, V., Hubner, K., Bauer, A., Orlova, I., Malapetsa, A., and Scholer, H.R. 2001. Comparative analysis of human, bovine, and murine Oct-4 upstream promoter sequences. *Mamm. Genome* **12**: 309–317.
- Pugh, C.W., Tan, C.C., Jones, R.W., and Ratcliffe, P.J. 1991. Functional analysis of an oxygen-regulated transcriptional enhancer lying 3' to the mouse erythropoietin gene. *Proc. Nat. Acad. Sci.* **88**: 10553–10557.
- Ramirez-Bergeron, D.L., Runge, A., Dahl, K.D., Fehling, H.J., Keller, G., and Simon, M.C. 2004. Hypoxia affects mesoderm and enhances hemangioblast specification during early development. *Development* **131**: 4623–4634.
- Ramos-Mejia, V., Escalante-Alcalde, D., Kunath, T., Ramirez, L., Gertsenstein, M., Nagy, A., and Lomeli, H. 2005. Phenotypic analyses of mouse embryos with ubiquitous expression of Oct4: Effects on mid-hindbrain patterning and gene expression. *Dev. Dyn.* **232**: 180–190.
- Raval, R.R., Lau, K.W., Tran, M.G., Sowter, H.M., Mandriota, S.J., Li, J.L., Pugh, C.W., Maxwell, P.H., Harris, A.L., and Ratcliffe, P.J. 2005. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. *Mol. Cell. Biol.* **25**: 5675–5686.
- Ryan, H.E., Lo, J., and Johnson, R.S. 1998. HIF-1 α is required for solid tumor formation and embryonic vascularization. *EMBO J.* **17**: 3005–3015.
- Saitou, M., Barton, S.C., and Surani, M.A. 2002. A molecular programme for the specification of germ cell fate in mice. *Nature* **418**: 293–300.
- Scholer, H.R., Dressler, G.R., Balling, R., Rohdewohld, H., and Gruss, P. 1990a. Oct-4: A germline-specific transcription factor mapping to the mouse t-complex. *EMBO J.* **9**: 2185–2195.
- Scholer, H.R., Ruppert, S., Suzuki, N., Chowdhury, K., and Gruss, P. 1990b. New type of POU domain in germ line-specific protein Oct-4. *Nature* **344**: 435–439.
- Scortegagna, M., Morris, M.A., Oktay, Y., Bennett, M., and Garcia, J.A. 2003. The HIF family member EPAS1/HIF-2 α is required for normal hematopoiesis in mice. *Blood* **102**: 1634–1640.
- Scortegagna, M., Ding, K., Zhang, Q., Oktay, Y., Bennett, M.J., Bennett, M., Shelton, J.M., Richardson, J.A., Moe, O., and

- Garcia, J.A. 2005. HIF-2 α regulates murine hematopoietic development in an erythropoietin-dependent manner. *Blood* **105**: 3133–3140.
- Semenza, G.L. 2000. HIF-1 and human disease: One highly involved factor. *Genes & Dev.* **14**: 1983–1991.
- Shimozaki, K., Nakashima, K., Niwa, H., and Taga, T. 2003. Involvement of Oct3/4 in the enhancement of neuronal differentiation of ES cells in neurogenesis-inducing cultures. *Development* **130**: 2505–2512.
- Spradling, A., Drummond-Barbosa, D., and Kai, T. 2001. Stem cells find their niche. *Nature* **414**: 98–104.
- Studer, L., Csete, M., Lee, S.H., Kabbani, N., Walikonis, J., Wold, B., and McKay, R. 2000. Enhanced proliferation, survival, and dopaminergic differentiation of CNS precursors in lowered oxygen. *J. Neurosci.* **20**: 7377–7383.
- Tai, M.H., Chang, C.C., Olson, L.K., and Trosko, J.E. 2005. Oct4 expression in adult human stem cells: Evidence in support of the stem cell theory of carcinogenesis. *Carcinogenesis* **26**: 495–502.
- Tian, H., McKnight, S.L., and Russell, D.W. 1997. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. *Genes & Dev.* **11**: 72–82.
- Velkey, J.M. and O'Shea, K.S. 2003. Oct4 RNA interference induces trophectoderm differentiation in mouse embryonic stem cells. *Genesis* **37**: 18–24.
- Wang, V., Davis, D.A., Haque, M., Huang, L.E., and Yarchoan, R. 2005. Differential gene up-regulation by hypoxia-inducible factor-1 α and hypoxia-inducible factor-2 α in HEK293T cells. *Cancer Res.* **65**: 3299–3306.
- Wenger, R.H. and Gassmann, M. 1997. Oxygen(es) and the hypoxia-inducible factor-1. *Biol. Chem.* **378**: 609–616.
- Wiesener, M., Turley, H., Allen, W., William, C., Eckardt, K., Talks, K., Wood, S., Gatter, K., Harris, A., Pugh, C., et al. 1998. Induction of endothelial PAS domain protein-1 by hypoxia: Characterization and comparison with hypoxia-inducible factor-1 α . *Blood* **92**: 2260–2268.
- Wiesener, M.S., Jurgensen, J.S., Rosenberger, C., Scholze, C.K., Horstrup, J.H., Warnecke, C., Mandriota, S., Bechmann, I., Frei, U.A., Pugh, C.W., et al. 2003. Widespread hypoxia-inducible expression of HIF-2 α in distinct cell populations of different organs. *FASEB J.* **17**: 271–273.
- Wilkinson, D. 1992. *In situ hybridization: A practical approach*. Oxford University Press, London.
- Wykoff, C.C., Sotiropoulos, C., Cockman, M.E., Ratcliffe, P.J., Maxwell, P., Liu, E., and Harris, A.L. 2004. Gene array of VHL mutation and hypoxia shows novel hypoxia-induced genes and that cyclin D1 is a VHL target gene. *Br. J. Cancer* **90**: 1235–1243.
- Yeom, Y.I., Fuhrmann, G., Ovitt, C.E., Brehm, A., Ohbo, K., Gross, M., Hubner, K., and Scholer, H.R. 1996. Germline regulatory element of Oct-4 specific for the totipotent cycle of embryonal cells. *Development* **122**: 881–894.

HIF-2 α regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth

Kelly L. Covello, James Kehler, Hongwei Yu, et al.

Genes Dev. 2006, **20**:

Access the most recent version at doi:[10.1101/gad.1399906](https://doi.org/10.1101/gad.1399906)

Supplemental Material

<http://genesdev.cshlp.org/content/suppl/2006/02/15/20.5.557.DC1>

References

This article cites 61 articles, 27 of which can be accessed free at:
<http://genesdev.cshlp.org/content/20/5/557.full.html#ref-list-1>

License

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).

Focused on your science.